Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Hematology | Internal Medicine | Oncology | Journal

Back to Journal Articles

No Adverse Effect of Statins Seen on Lymphoma Outcomes

Last Updated: December 16, 2009.

 

Statin use not found to adversely affect outcomes in patients treated with rituximab

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Statins have no effect on outcomes in patients with B-cell lymphoma treated with rituximab, but improve event-free survival in patients with follicular lymphoma regardless of rituximab treatment, according to a study published online Dec. 14 in the Journal of Clinical Oncology.

WEDNESDAY, Dec. 16 (HealthDay News) -- Statins have no effect on outcomes in patients with B-cell lymphoma treated with rituximab, but improve event-free survival in patients with follicular lymphoma regardless of rituximab treatment, according to a study published online Dec. 14 in the Journal of Clinical Oncology.

Noting that statins can block the binding of rituximab to its target, Grzegorz S. Nowakowski, M.D., and colleagues from the Mayo Clinic in Rochester, Minn., examined the impact of statin use on rituximab efficacy in 228 patients with newly diagnosed, diffuse large B-cell lymphoma (21 percent taking statins) and in 293 patients with follicular lymphoma (19 percent taking statins). All diffuse large B-cell lymphoma patients and 39 percent of follicular lymphoma patients were initially treated with rituximab.

After a median follow-up of 47 months, the researchers found that statin use had no significant impact on overall response, overall survival, or event-free survival in patients with diffuse large B-cell lymphoma (hazard ratio, 0.85). Statins improved event-free survival in patients with follicular lymphoma (hazard ratio, 0.45), including patients treated with rituximab (hazard ratio, 0.38) and untreated patients (hazard ratio, 0.38).

"The concurrent use of statins during the treatment of patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era did not adversely affect outcome," Nowakowski and colleagues conclude.

One author reported a financial and consulting relationship with Genentech.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: American Association for Respiratory Care, Dec. 5-8, 2009 Next: American Indians Have Far Higher H1N1 Flu Death Rate

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.